Skip to main content
SpringerLink
Log in

Polymorphisms in the human CYP1A1 gene as susceptibility factors for lung cancer: exon-7 mutation (4889 A to G), and a T to C mutation in the 3′-flanking region

  • Molecular Medicine
  • Published:
The clinical investigator Aims and scope Submit manuscript

Abstract

Genetic differences in the metabolism of carcinogens may codetermine individual predisposition to cancer. Cytochrome P-4501A1 (CYP1A1) metabolically activates precarcinogens in cigarette smoke, such as benzo(a)pyrene, which is also an inducer of CYP1A1. Two point mutations have been reported, m1 in the 3′-flanking region (6235T to C), and m2 within exon 7 (4889A to G), the latter leading to an isoleucine to valine exchange. In the Japanese population ml and m2 are correlated with lung cancer, suggesting an increased susceptibility to cigarette smoking related lung cancer. We studied 142 lung cancer and 171 reference patients in an ethnically homogeneous German group for m1 and m2 mutations by restriction fragment length polymorphism and allele-specific polymerase chain reaction, respectively. No statistically significant difference was found in the distribution of m1 alleles between lung cancer and controls; the frequency was 8.5% and 7.3% of the alleles, respectively (odds ratio = 1.17). A trend to an overrepresentation of ml alleles was observed among 52 squamous cell carcinoma patients (odds ratio = 1.65). In contrast, the frequency of m2 alleles in lung cancer patients was twofold higher (6.7%) than in the reference group (3.2%; odds ratio = 2.16; 95% confidence limits 0.96–5.11, P = 0.033); the odds ratio of m2 alleles in squamous cell carcinoma was 2.51 (95% confidence limits 0.85–7.05, P = 0.05). There was a close genetic linkage of m2 to m1 (10 of 11 reference patients), but a significantly higher number of cancer patients showed no linkage compared to the controls (odds ratio = 8.89, 95% confidence limits 0.83–433, P = 0.04). Thus no association was found between presence of ml alleles and lung cancer, but, in contrast, m2 alleles proved as a hereditary risk factor, especially if not linked with m1 alleles.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Abbreviations

Ah:

aryl hydrocarbon

CYP1A1:

cytochrome P4501A1

CYP1A1 :

CYP1A1 gene

PCR:

polymerase chain reaction

PY:

pack years

RFLP:

restriction fragment length polymorphism

References

  1. Bale AE, Nebert DW, McBride OW (1987) Subchromosomal localization of the dioxin-inducible P 1-450 locus (CYP1) and description of two RFLPs detected with a 3′ P 1-450 cDNA probe. Cytogenet Cell Genet 46:574–5751

    Google Scholar 

  2. Brockmöller J, Kerb R, Drakoulis N, Nitz M, Roots I (1993) Genotype and phenotype of glutathione S-transferase class μ isoenzymes μ and ψ in lung cancer patients and controls. Cancer Res 53:1004–1011

    Google Scholar 

  3. Drakoulis N, Beland M, Roots I (1991) Determination of arylamine N-acetyltransferase genotype in humans. Naunyn-Schmiedebergs Arch Pharmacol 344 [Suppl]: R88

    Google Scholar 

  4. Fujii-Kuriyama Y, Imataka H, Sogawa K, Yasumoto KI, Kikuchi Y (1992) Regulation of CYP1A1 expression. FASEB J 6:706–710

    Google Scholar 

  5. Gonzalez FJ, Liu SY, Yano M (1993) Regulation of cytochrome P450 genes: molecular mechanisms. Pharmacogenetics 3:51–57

    Google Scholar 

  6. Guengerich FP, Shimada T (1991) Oxidation of toxic and carcinogenic chemicals by human cytochrome P-450 enzymes. Chem Res Toxicol 4:391–407

    Google Scholar 

  7. Hayashi S, Watanabe J, Nakachi K, Kawajiri K (1991) Genetic linkage of lung cancer-associated MspI polymorphism with amino acid replacement in the heme binding region of the human cytochrome P450IA1 gene. J Biochem 110:407–411

    Google Scholar 

  8. Hirvonen A, Husgafvel-Pursiainen K, Anttila S, Karjalainen A, Sorsa M, Vainio H (1992) Metabolic cytochrome P450 genotypes and assessment of individual susceptibility to lung cancer. Pharmacogenetics 2:259–263

    Google Scholar 

  9. Ingelman-Sundberg M, Johansson I, Persson I, Yue QY, Dahl ML, Bertilsson L, Sjögvist F (1992) Genetic polymorphism of cytochromes P450: interethnic differences and relationship to incidence of lung cancer. Pharmacogenetics 2:264–271

    Google Scholar 

  10. Jaiswal AK, Gonzalez FJ, Nebert DW (1985) Human P1-450 gene sequence and correlation of mRNA with genetic differences in benzo(a)pyrene metabolism. Nucleic Acids Res 13:4503–4520

    Google Scholar 

  11. Kawajiri K, Watanabe J, Gotoh O, Tagashira Y, Sogawa K, Fujii-Kuriyama Y (1986) Structure and drug inducibility of the human cytochrome P-450c gene. Eur J Biochem 159:219–225

    Google Scholar 

  12. Kawajiri K, Nakachi K, Imai K, Yoshii A, Shinoda N, Watanabe I (1990) Identification of genetically high risk individuals to lung cancer by DNA polymorphisms of cytochrome P4501A1 gene. FEBS Lett 263:131–133

    Google Scholar 

  13. Kawajiri K, Nakachi K, Imai K, Watanabe J, Hayashi S (1993) The CYP1A1 gene and cancer susceptibility. Crit Rev Oncol Hematol 14:77–87

    Google Scholar 

  14. Kouri RE, McKinney CE, Slomianry DJ, Snodgrass DR, Wray NP, McLemore TL (1982) Positive correlation between high aryl hydrocarbon hydroxylase activity and primary lung cancer as analyzed in cryopreserved lymphocytes. Cancer Res 42:5030–5037

    Google Scholar 

  15. McLemore TL, Adelberg S, Liu MC, McMahon NA, Yu SJ, Hubbard WC, Czerwinski M, Wood TG, Storeng R, Lubet RA, Eggleston JC, Boyd MR, Hines RN (1990) Expression of CYP1A1 gene in patients with lung cancer: evidence for cigarette smoke induced gene expression in normal lung tissue and for pulmonary carcinomas. J Natl Cancer Inst 82:1333–1339

    Google Scholar 

  16. Nakachi K, Imai K, Hayashi S, Watanabe J, Kawajiri K (1991) Genetic susceptibility to squamous-cell carcinoma of the lung in relation to cigarette smoking dose. Cancer Res 51:5177–5180

    Google Scholar 

  17. Nebert DW, Petersen DD, Puga A (1991) Human AH locus polymorphism and cancer: inducibility of CYP1A1 and other genes by combustion products and dioxin. Pharmacogenetics 1:68–78

    Google Scholar 

  18. Petersen DD, McKinney CE, Ikeya K, Smith HH, Bale AE, McBride OW, Nebert DW (1991) Human CYP1A1 gene: cosegregation of the enzyme inducibility phenotype and an RFLP. Am J Hum Genet 48:720–725

    Google Scholar 

  19. Roots I, Drakoulis N, Ploch M, Heinemeyer G, Loddenkemper R, Minks T, Nitz M, Otte F, Koch M (1988) Debrisoquine hydroxylation phenotype, acetylation phenotype, and AB0 blood groups as genetic host factors of lung cancer risk. Klin Wochenschr 66 [Suppl XI]:87–97

    Google Scholar 

  20. Roots I, Brockmöller J, Drakoulis N, Loddenkemper R (1992) Mutant genes of cytochrome P-450IID6, glutathione S-transferase class mu, and arylamine N-acetyltransferase in lung cancer patients. Clin Investig 70:307–319

    Google Scholar 

  21. Roots I, Drakoulis N, Brockmöller J (1992) Polymorphic enzymes and cancer risk: concepts, methodology and data review. In: Kalow W (ed) Pharmacogenetics of drug metabolism. Pergamon, New York, pp 815–841

    Google Scholar 

  22. Rost KL, Brösicke H, Brockmöller J, Scheffler M, Helge H, Roots I (1992) Increase of cytochrome P450IA2 activity by omeprazole: evidence by the 13C-[N-3-methyl]-caffeine breath test in poor and extensive metabolizers of S-mephenytoin. Clin Pharmacol Ther 52:170–180

    Google Scholar 

  23. Sambrock J, Fritsch EF, Maniatis T (1989) Molecular cloning: a laboratory manual, 2nd edn. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York

    Google Scholar 

  24. Schlesselman JJ (1974) Sample size requirements in cohort and case-control studies of disease. Am J Epidemiol 99:381–384

    Google Scholar 

  25. Shields PG, Sugimura H, Caporaso NE, Petruzelli SF, Bowman ED, Trump BF, Weston A, Harris CC (1992) Polycyclic aromatic hydrocarbon-DNA adducts and the CYP1A1 restriction fragment length polymorphism. Environ Health Perspect 98:191–194

    Google Scholar 

  26. Spurr NK, Gough AC, Stevenson K, Wolf CR (1987) MspI-polymorphism detected with a cDNA probe for the P-450 I family on chromosome 15. Nucleic Acids Res 15:5901

    Google Scholar 

  27. Tassaneeyakul W, Birkett DJ, Veronese ME, McManus ME, Tukey RH, Quattrochi LC, Gelboin HV, Miners JO (1993) Specificity of substrate and inhibitor probes for human cytochromes P450 1A1 and 1A2. J Pharmacol Exp Ther 265:401–407

    Google Scholar 

  28. Tefre T, Ryberg D, Haugen A, Nebert DW, Skaug V, Brøgger A, Borresen AL (1991) Human CYP1A1 (cytochrome P1450) gene: lack of association between the MspI restriction fragment length polymorphism and incidence of lung cancer in a Norwegian population. Pharmacogenetics 1:20–25

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institut für Klinische Pharmakologie, Medizinische Fakultät (Charité), Humboldt-Universität zu Berlin, D-10098, Berlin, Germany

    N. Drakoulis, I. Cascorbi, J. Brockmöller, C. R. Gross & I. Roots

Authors
  1. N. Drakoulis
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. I. Cascorbi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J. Brockmöller
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. C. R. Gross
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. I. Roots
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

Correspondence to: N. Drakoulis

Rights and permissions

Reprints and permissions

About this article

Cite this article

Drakoulis, N., Cascorbi, I., Brockmöller, J. et al. Polymorphisms in the human CYP1A1 gene as susceptibility factors for lung cancer: exon-7 mutation (4889 A to G), and a T to C mutation in the 3′-flanking region. Clin Investig 72, 240–248 (1994). https://doi.org/10.1007/BF00189321

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00189321

Key words

Search

Navigation